ADAM TELERMAN M.D., Ph.D.
ADDRESS Tumor reversion Lab INSERM U981 Institut Gustave Roussy, Bâtiment B2M 114 rue Edouard Vaillant 94805 Villejuif, France
email atelerman@gmail.com
BORN June 15, 1954. CITIZENSHIP. Belgian, permanent resident in Paris, France
DEGREES AND EDUCATION
M.D., Ph.D - Medical School: 7 year program. Free University of Brussels (June 1980). Cum Laude - Specialist in Internal Medicine and Hematology/Oncology, Free University of Brussels (June 1985)
Professorship thesis and Ph.D. (May 1989): Agrégé de l'Enseignement Supérieur, Free University of Brussels
POSITIONS
1. Research Director (CNRS), INSERM U981, Institut Gustave Roussy (2014 - present) Biology, Genetics and Pharmacology of Tumor reversion.
2. Research Director (CNRS), LBPA, UMR 8113, Ecole Normale Supérieure, Cachan, France (2007- 2014) Biology. Genetics and Pharmacology of Tumor reversion.
3. Member-visitor, Institute for Advanced Study, Princeton, USA (2006).
4. Director, Cancer Research , Molecular Engines Laboratories (2000- 2006) Founder Molecular Engines Laboratories (2000) Molecular and functional characterization of the tumor reversion pathways Biological models and genes of tumor reversion Conditional knock out mice for 3 genes Crystal structure of target proteins Drug discovery with one pharmaceutical compound in a phase I/II clinical trial in AML
5. Director, Cancer Genetics Program. Fondation Jean Dausset - CEPH (1994- 2000) Molecular characterization of the tumor reversion pathways.
6. Professeur Agrégé de l'Enseignement Supérieur (Association Against Cancer) (1989-1994) Institute of Interdisciplinary Research, Faculty of Medicine. Free University of Brussels. Oncogenes and tumor suppressor genes in human leukemias. Initiation of research on biological models of tumor reversion.
7. Senior Investigator (Chargé de Recherche au Fonds National de la Recherche Scientifique) (1987-1989). Institute of Interdisciplinary Research, Faculty of Medicine. Free University of Brussels. Oncogenes in human leukemias.
8. EMBO long-term postdoctoral fellow (1985-1987) Weizmann Institute of Science, Department of Chemical Immunology (David Givol), Rehovot, Israel. Oncogenes in human leukemias.
9. Fulbright Fellow (1983-1984) Memorial Sloan-Kettering Cancer Center, New York (Professor C.D. Platsoucas) Research on the association of CD3-T cell antigen receptor, T-T cell hybridomas, Tumor Necrosis Factor
10. Research during training in Internal Medicine a) Faculty of Medicine (Professor P. Galand), Department of Immunology and Hôpital Erasme (1984-1985) Endocytosis of T-cell receptors, T cell activation b) Department of General Chemistry (Professor A.G. Schnek, J-P Prieels) (1983) Research on the biochemistry of iron binding molecules (lactoferrin). Analysis of glycoproteins of human T and B leukemic cell lines. Analysis of specific enzyme activities of leukemic B and T lymphocytes (Galactosyltransferase, fucosyltransferase, sialyltransferase)
11. Research during medical studies Institut Jules Bordet, Laboratory of Experimental Hematology (Professor P. Stryckmans) (1978-1981) Research on committed stem cells of the eosinophilic lineage (CFUeo) Investigations on lactoferrin as a regulator of hematopoiesis
TEACHING
Molecular biology and genetics of cancer (ENS Cachan and Université Paris 11 M1-M2 de Cancérologie and Ecole doctorale de cancérologie).
HOSPITAL EXPERIENCE IN THE UNITED STATES:
Memorial Sloan-Kettering Cancer Center, New York. Department of Hematology-Lymphoma. Fulbright Fellow, 1 year (1983-1984)
Mount Sinai School of Medicine. Department of Hematology (1978)
Harvard Medical School, Peter Bent Brigham Hospital, Department of Hematology (1979)
Harvard Medical School, Beth Israel Hospital, Department of Hematology (1979, 1980)
TRAINING IN INTERNAL MEDICINE
1980-81: Institut Jules Bordet, Free University of Brussels 1981-83: Hôpital de Saint Gilles, Free University of Brussels 1983-84: Memorial Sloan-Kettering Cancer Center, New York, USA 1984-85: Hôpital Erasme, Free University of Brussels
HONORS, FELLOWSHIPS AND GRANTS:
SATT 2019-2020, 580.00 € - INCA Projets libres de recherche « Biologie et Sciences du Cancer » (2013-2017) - LabEx LERMIT (2012- 2018). - Agence Nationale de la Recherche Programme (ANR) Blanc, 680.000 € (2009-2012). - Association Sclérose Tubéreuse de Bourneville (2010-2011). - 7th Framework Programme, Conticanet, Network of Excellence, European Union, 220.000 € (18 months: 2009-2010). - 6th Framework Programme, Conticanet, Network of Excellence, European Union, 220.000 € (18 months: March 2008-2009). - European Community Grant: EUREKA 1,050,000 € (2003-2004) - ANVAR, Ministry of Health, 1,100,000 € (2000-2004) - Crédit Impôt Recherche, 2,700,000 € (2000-2004) - Fondation Jean Dausset, 6,000,000 € (1994-2000) - Fonds National de la Recherche Scientifique (FNRS) (1987-1995) - Association Against Cancer (1989-1994) - FNRS: Chargé de Recherches (1987-1989) - Grant: Fondation Emile Defay (1989) - Grant: Commission crédits de recherche U.L.B. (1988) - EMBO Long-Term postdoctoral fellowship (1985-87) - Fulbright Award for Research. Commission of Education, Congress of the USA (1983-84) - Recipient of studies award in Medicine, Belgian Ministry of Health (1973-80) January 2016 CV Adam Telerman, page 3 PRIVATE INVESTMENTS: 17,100,000 € (2000-2004) -HBM BioVentures AG (Switzerland) -3i (Germany) -VENTECH (France) -ODYSSEE VENTURE (France) -Technologieholdung (Germany) -NMT Management AG (Switzerland)
LANGUAGES : French, English, Dutch, Polish, German, Italian, Hebrew